TerminatedPhase 1NCT03893682
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
Studying B-cell chronic lymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Aptose Biosciences Inc.
- Principal Investigator
- Rafael Bejar, MD, PhD, M.D., PhDAptose Biosciences Inc.
- Intervention
- CG-806(drug)
- Enrollment
- 36 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2024
Study locations (30)
- University of California Los Angeles, Los Angeles, California, United States
- Pacific Cancer Care, Monterey, California, United States
- Torrance Memorial Physician Network, Redondo Beach, California, United States
- UCSD Moores Cancer Center, San Diego, California, United States
- Sharp Clinical Oncology Research, San Diego, California, United States
- Ridley-Tree Cancer Center, Santa Barbara, California, United States
- St. Joseph Heritage Heathcare, Santa Rosa, California, United States
- Rocky Mountain Cancer Centers, Aurora, Colorado, United States
- Mayo Clinic Jacksonville, Jacksonville, Florida, United States
- Orlando Health, Orlando, Florida, United States
- Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
- University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
- The Center for Cancer and Blood Disorders a division of American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
- UMass Memorial Medical Center, Worcester, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03893682 on ClinicalTrials.govOther trials for B-cell chronic lymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center
- RECRUITINGEARLY PHASE1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE4NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and Company
- RECRUITINGPHASE1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center
- RECRUITINGPHASE2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPHASE2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer
- RECRUITINGPHASE2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn